Chembio Diagnostics - 14 Year Stock Price History | CEMI

Historical daily share price chart and data for Chembio Diagnostics since 2004 adjusted for splits and dividends. Open, high, low, close (OHLC) data as well as percentage changes for multiple date ranges. Display 20, 50 and 200 day moving averages and export charts as images to use in articles and blogs. The latest closing price for Chembio Diagnostics as of December 18, 2018 is 5.60.
Chembio Diagnostics Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2018 8.8952 8.1000 11.5000 5.6000 5.6000 -31.71%
2017 6.2502 6.6500 8.3500 5.2500 8.2000 20.59%
2016 6.7890 5.2100 9.1200 4.2800 6.8000 27.58%
2015 4.5294 3.8700 5.3400 3.5600 5.3300 36.32%
2014 3.5915 3.4000 4.7300 2.8700 3.9100 16.02%
2013 4.4190 4.7501 5.7100 3.2900 3.3700 -28.75%
2012 4.3034 3.4400 5.2599 3.2800 4.7300 40.77%
2011 3.4753 3.2800 4.5600 2.4800 3.3600 -1.18%
2010 2.1713 2.1600 3.6400 1.5200 3.4000 51.79%
2009 1.3250 0.8800 2.9600 0.6400 2.2400 154.55%
2008 1.3837 1.9200 2.4000 0.6000 0.8800 -59.26%
2007 4.6029 6.1600 7.2000 2.1600 2.1600 -67.47%
2006 5.8140 3.0400 8.2400 2.6400 6.6400 137.14%
2005 4.8378 5.7600 6.5600 2.4400 2.8000 -51.39%
Sector Industry Market Cap Revenue
Medical Medical Products Manufacturing $0.101B $0.024B
CHEMBIO DIAGNOSTICS, INC. develops, manufactures, licenses and markets proprietary rapid diagnostic tests in the growing $5 billion point-of-care testing market. Chembio's two FDA PMA-approved, CLIA-waived, rapid HIV tests are marketed in the U.S. by a third party company. Chembio markets its HIV STAT-PAK line of rapid HIV tests internationally to government and donor-funded programs directly and through distributors. Chembio also has rapid tests for veterinary tuberculosis and chagas disease. In 2007 Chembio received a U.S. patent for its Dual Path Platform technology which has significant advantages over lateral-flow technologies. This technology is providing Chembio with a significant pipeline of business opportunities for the development and manufacture of new products based on DPP. Chembio is licensed by the U.S. Food and Drug Administration as well as the U. S. Department of Agriculture, and is certified for the global market under the International Standards Organization directive 13.485.
Stock Name Country Market Cap PE Ratio
Medtronic (MDT) Ireland $123.359B 18.44
Abbott Laboratories (ABT) United States $122.504B 24.82
Stryker (SYK) United States $59.911B 22.58
Boston Scientific (BSX) United States $47.118B 23.81
Baxter (BAX) United States $34.158B 22.06
Zimmer Biomet Holdings (ZBH) United States $21.876B 14.19
Smith & Nephew SNATS (SNN) United Kingdom $16.204B 0.00
ResMed (RMD) United States $15.783B 30.10
Perrigo (PRGO) Ireland $7.660B 11.63
Bio-Rad Laboratories (BIO) United States $7.281B 46.56
Canopy Growth (CGC) Canada $6.819B 0.00
Hill-Rom Holdings (HRC) United States $6.051B 18.93
Aurora Cannabis (ACB) Canada $5.521B 29.16
Haemonetics (HAE) United States $5.243B 46.11
Insulet (PODD) United States $4.521B 0.00
ICU Medical (ICUI) United States $4.481B 24.97
Hutchison China MediTech (HCM) China $4.254B 0.00
GW Pharmaceuticals (GWPH) United Kingdom $3.594B 0.00
Neogen (NEOG) United States $3.108B 47.06
Agios Pharmaceuticals (AGIO) United States $2.958B 0.00
NuVasive (NUVA) United States $2.733B 25.43
National Vision Holdings (EYE) United States $2.256B 43.63
Quidel (QDEL) United States $1.932B 25.18
NxStage Medical (NXTM) United States $1.877B 0.00
Aphria (APHA) $1.356B 0.00
Phibro Animal Health (PAHC) United States $1.315B 18.61
AtriCure (ATRC) United States $1.130B 0.00
Cardiovascular Systems (CSII) United States $0.974B 1402.00
VAREX IMAGING (VREX) United States $0.891B 17.84
PetIQ (PETQ) United States $0.812B 21.04
Cerus (CERS) United States $0.741B 0.00
Meridian Bioscience (VIVO) United States $0.736B 23.45
Surmodics (SRDX) United States $0.721B 109.84
OraSure Technologies (OSUR) United States $0.705B 39.69
Eagle Pharmaceuticals (EGRX) United States $0.660B 21.18
Omeros (OMER) United States $0.643B 0.00
Lantheus Holdings (LNTH) United States $0.626B 19.38
MacroGenics (MGNX) United States $0.566B 0.00
LeMaitre Vascular (LMAT) United States $0.476B 23.36
NanoString Technologies (NSTG) United States $0.470B 0.00
Owens & Minor (OMI) United States $0.411B 4.65
Quanterix (QTRX) United States $0.409B 0.00
TG Therapeutics (TGTX) United States $0.369B 0.00
Insys Therapeutics (INSY) United States $0.356B 0.00
Evolus (EOLS) United States $0.336B 0.00
Utah Medical Products (UTMD) United States $0.304B 19.69
VAPOTHERM INC (VAPO) United States $0.294B 0.00
Cytosorbents (CTSO) United States $0.282B 0.00
Surface Oncology (SURF) United States $0.216B 0.00
Neptune Technologies & Bioresources Inc (NEPT) Canada $0.213B 0.00
Bovie Medical (BVX) United States $0.198B 0.00
BioLife Solutions (BLFS) United States $0.196B 265.00
Rockwell Medical (RMTI) United States $0.163B 0.00
Chimerix (CMRX) United States $0.152B 0.00
Fonar (FONR) United States $0.133B 6.69
Imprimis Pharmaceuticals (IMMY) United States $0.125B 0.00
Female Health (VERU) United States $0.088B 0.00
United-Guardian (UG) United States $0.076B 15.96
Oramed Pharmaceuticals (ORMP) United States $0.067B 0.00
InfuSystems Holdings (INFU) United States $0.067B 0.00
Trinity Biotech (TRIB) Ireland $0.062B 17.07
CAS Medical Systems (CASM) United States $0.044B 0.00
Conatus Pharmaceuticals (CNAT) United States $0.042B 0.00
ImmuCell (ICCC) United States $0.040B 0.00
Neurotrope (NTRP) United States $0.031B 0.00
Myomo (MYO) United States $0.021B 0.00
InVivo Therapeutics Holdings (NVIV) United States $0.016B 0.00
Capricor Therapeutics (CAPR) United States $0.016B 0.00
Senestech (SNES) United States $0.014B 0.00
Akers Biosciences Inc (AKER) United States $0.012B 0.00
Cellectar Biosciences (CLRB) United States $0.010B 0.00
Valeritas Holdings (VLRX) United States $0.009B 0.00
NeuroMetrix (NURO) United States $0.006B 0.00